↓ Skip to main content

Dove Medical Press

Zonisamide in the management of epilepsy in the elderly

Overview of attention for article published in Clinical Interventions in Aging, June 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Readers on

mendeley
87 Mendeley
Title
Zonisamide in the management of epilepsy in the elderly
Published in
Clinical Interventions in Aging, June 2015
DOI 10.2147/cia.s50819
Pubmed ID
Authors

Andrea Romigi, Eti A Femia, Cinzia Fattore, Giuseppe Vitrani, Giancarlo Di Gennaro, Valentina Franco

Abstract

Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed.

Timeline
X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Colombia 1 1%
Unknown 86 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 26 30%
Student > Ph. D. Student 6 7%
Researcher 6 7%
Other 5 6%
Student > Master 5 6%
Other 14 16%
Unknown 25 29%
Readers by discipline Count As %
Nursing and Health Professions 21 24%
Medicine and Dentistry 14 16%
Pharmacology, Toxicology and Pharmaceutical Science 12 14%
Psychology 3 3%
Agricultural and Biological Sciences 2 2%
Other 9 10%
Unknown 26 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2015.
All research outputs
#16,868,837
of 25,584,565 outputs
Outputs from Clinical Interventions in Aging
#1,168
of 1,962 outputs
Outputs of similar age
#159,689
of 281,752 outputs
Outputs of similar age from Clinical Interventions in Aging
#23
of 43 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,962 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,752 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.